Chronic kidney disease in the elderly: is it really a premise for overwhelming renal failure?  by Locatelli, F. & Pozzoni, P.
2118   Kidney International (2006) 69
commentar y
Hypercalciuria is a feature of patients 
carrying the WNK4 Q562E mutation and 
is not present in patients carrying WNK1 
mutations. As disease-causing mutations 
of WNK4 enhance TRPV5 to an extent 
comparable to that of wild-type WNK4 
(J-B Peng et al., J Am Soc Nephrol 2004; 
15: 62A, abstr.), it may be that other fac-
tors come into play in the hypercalciuria 
seen in PHA II. Distal tubular calcium 
reabsorption is inversely related to sodium 
reabsorption, and therefore the increase 
in calcium excretion may be linked to the 
elevation in distal tubular sodium reab-
sorption. In addition, the transcellular 
epithelial calcium channels TRPV5 and 
TRPV6 are also inhibited by acidosis.
Finally, WNK1 is also a regulator of the 
ion transporters ENaC and ROMK, which 
may provide a basis for the role of WNK1 
in the molecular pathogenesis of PHA II. 
New lines of evidence indicate that WNK1 
and WNK4 are upstream of two STE20-
type kinases, SPAK and OSR1, that regulate 
members of the SLC12A family of elec-
troneutral cation-Cl– cotransporters.10,11 
Th us, identifying at a cellular and molecu-
lar level the diff erences between wild-type 
WNK4 and disease-causing mutants and 
their eff ects on transport protein activity 
and expression levels should provide fur-
ther insight into the mechanisms underly-
ing the pathogenesis of PHA II.
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Chronic kidney disease in the 
elderly: is it really a premise for 
overwhelming renal failure?
F Locatelli1 and P Pozzoni1
Increasingly, the majority of patients being diagnosed as affected by 
chronic kidney disease (CKD) are elderly. Nonetheless, only a rather 
small proportion of elderly CKD patients actually progress to end-stage 
renal disease, whereas many more die before this stage is reached, 
largely because of cardiovascular disease. This underscores the urgent 
need for cardiovascular prevention, even more importantly than for 
renoprotection, among elderly patients with CKD.
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Chronic kidney disease (CKD) is becom-
ing increasingly common. The United 
States Renal Data System has reliably 
estimated that the number of patients on 
maintenance dialysis in the United States 
will double over the next few years,1 and a 
relatively large number of newly diagnosed 
CKD patients every year (incident CKD 
patients) are elderly. In Europe, an epide-
miological survey of the Île-de-France area 
showed a striking age-related increase in 
the annual incidence of CKD (that is, the 
fi rst evidence of serum creatinine levels 
greater than 2 mg per dl in the course of 
1 year): the incidence rate among patients 
aged more than 75 years was almost seven 
times that of patients aged 20–39 years 
(619 versus 92 new cases per million 
population) and more than twice that of 
patients aged 40–59 years (619 versus 264 
new cases per million population).2 Th e 
increased incidence of CKD among the 
elderly translates into a similarly increased 
prevalence: the Th ird National Health and 
Nutrition Examination Survey (NHANES 
III) of a nationally representative sample of 
adults in the United States between 1988 
and 1994 found that 7.6% of the individu-
als aged 60–69 years, and 25.9% of those 
aged at least 75 years, had a glomerular 
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filtration rate (GFR) of 15–60 ml per 
minute per 1.73 m2, as against only 1.8% of 
those aged 40–59 years and 0.2% of those 
aged less than 40 years.3
At the same time, and in the face of this 
tsunami-like wave of CKD aff ecting partic-
ularly older subjects, there is growing and 
apparently paradoxical evidence that there 
are considerably fewer patients on chronic 
dialysis than patients in the earlier stages 
of CKD. Th e NHANES III fi ndings make it 
possible to estimate that 4.7% of the United 
States population (about 8.3 million indi-
viduals) has GFR levels less than 60 ml 
per minute per 1.73 m2, which becomes 
11.0% (19.5 million) when we also con-
sider people with slightly decreased kidney 
function (GFR 60–90 ml per minute per 
1.73 m2, CKD stage 2) and those with only 
persistent albuminuria (CKD stage 1);3 
these numbers greatly exceed the 102,000 
who started chronic dialysis in the United 
States in 2003, and even the 537,000 prev-
alent dialysis patients treated during the 
same year.4 Th e main explanation for this 
discrepancy between the ‘social’ burden of 
CKD and that of renal replacement treat-
ments is that the number of CKD patients 
progressing toward a degree of renal failure 
that requires replacement treatment for 
survival is much lower than the number 
of patients who die before they reach 
the point of end-stage renal disease, as is 
clearly shown by Keith et al.5 and Foley et 
al.,6 and this is largely due to the eff ects 
of cardiovascular disease. Th ese observa-
tions further underline what is already 
known to be the devastating impact of 
cardiovascular disease on the long-term 
clinical outcomes of CKD patients and 
stress the urgent need for strategies aimed 
at preventing not only the progression of 
CKD per se, but also the development of 
cardiovascular complications.
In this issue, Hemmelgarn et al.7 report 
that, even in a very large community-based 
population, only a rather small propor-
tion (0.9%) of elderly CKD patients actu-
ally progressed to end-stage renal disease, 
whereas three times as many died during 
the same period. Such a relatively high 
mortality rate is of course not surprising, 
as the mean age of the study population 
was more than 75 years, but it is worth 
noting that only a minority (about 20%) 
of even subjects with a baseline GFR of less 
than 30 ml per minute per 1.73 m2 began 
dialysis during the study. Th e patients with 
the lowest GFR at baseline were probably 
the most progressive, and so it is not sur-
prising that they showed the highest rate of 
decline in renal function over time. Unfor-
tunately, the median follow-up of 2 years 
was probably too short to allow a com-
plete analysis of the longitudinal changes 
in renal function, which tends to limit the 
applicability of the results to the whole 
population of elderly CKD patients.
Unfortunately, in the study by Hem-
melgarn et al.7 there is no information 
concerning the underlying nephropathy 
or other variables, such as blood pressure 
and proteinuria levels, which are known to 
be the most important factors aff ecting the 
progression of CKD. Above all, although it 
was stratifi ed by diabetes mellitus, gender, 
and baseline renal function, the analysis of 
the changes in GFR over time did not con-
sider the drugs the patients were taking (in 
particular, angiotensin-converting enzyme 
inhibitors and angiotensin receptor block-
ers) or the degree of blood pressure con-
trol reached with and without them. Th e 
only information provided on this point is 
that drugs blocking the renin–angiotensin 
system were taken by increasing propor-
tions of the patients with decreasing base-
line renal function, which means that the 
patients who progressed most during the 
study were signifi cantly more treated with 
the drugs that should have protected them 
against progression. It is likely that this 
association can be explained by selection 
bias, because it is realistic to presume that 
the patients showing a faster rate of pro-
gression were more likely to be managed 
by well-known nephroprotective agents; 
but although only one-third of the patients 
with a baseline GFR of more than 60 ml 
per minute per 1.73 m2 were taking angio-
tensin-converting enzyme inhibitors and/
or angiotensin receptor blockers, their rate 
of decline in renal function over the dura-
tion of the study was very slow (a mean of 
0.6 ml per minute per 1.73 m2 per year). 
Th is last observation raises the question 
of whether we should reconsider the role 
of renin–angiotensin system blockade as a 
means of protecting against the progression 
of CKD, at least in contexts such as elderly 
populations in which the burden of overt 
proteinuric nephropathies is believed to be 
lower than in other populations and there 
is a greater potential risk of further deterio-
ration of renal function because of the high 
prevalence of renal stenotic atherosclerotic 
lesions and very frequent concomitant use 
of diuretics and nonsteroidal anti-infl am-
matory drugs. It can likewise be argued 
that epidemiological surveys should be 
analyzed more cautiously, as it has been 
perhaps too oft en claimed that the recent 
reduction in the number of patients reach-
ing end-stage renal disease is mainly due 
to the increasing administration of drugs 
capable of counteracting progressive kid-
ney damage.
It is also particularly interesting to 
note that only a relatively small propor-
tion of the CKD population enrolled in 
the study made use of drugs that have 
the documented potential to prevent the 
development of cardiovascular events 
(angiotensin-converting enzyme inhibi-
tors, angiotensin receptor blockers, beta 
blockers, statins).7 Although it is neces-
sary to remember the intrinsic limitations 
of observational studies and the fact that 
the theoretical benefi ts of such drugs must 
always be weighed against their frequent 
adverse effects, particularly in elderly 
patients, these numbers suggest that there 
are still ample margins for improving 
the prevention of cardiovascular disease 
among CKD patients.
Th e fi ndings of this and previous stud-
ies have very important implications not 
only for patients and their families, but also 
for health-care providers, because the slow 
rate of renal-function decline in the elderly 
CKD population will lead in the near future 
to a smaller number of patients requiring 
long-term dialysis than expected, and pub-
lic-health programs can be adjusted on the 
grounds that the need for dialysis centers 
may be much less than foreseen only a 
few years ago. Finally, without neglecting 
the importance of therapeutic strategies 
aimed at slowing down the progression of 
renal damage in CKD patients, this study 
provides further evidence that the nephro-
logical management particularly of elderly 
CKD patients should fi rst of all concentrate 
on therapeutic options aimed at prevent-
ing or decreasing the development of the 
cardiovascular abnormalities that cause the 
death of these patients before they reach 
the need for chronic dialysis.
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Interpreting cost-effectiveness in 
dialysis: can the most expensive 
be more expensive?
PA McFarlane1
In this issue, Tonelli et al. describe the cost-effectiveness of 
arteriovenous fistulae (AVF) screening, and conclude that such a 
program represents “good value for money.” Here, I examine the 
robustness of this conclusion by considering traditional definitions of 
acceptable cost-effectiveness and more pragmatic definitions, which 
include consideration of the maximum amount that society would be 
willing to pay for hemodialysis.
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In this issue, Tonelli and colleagues1 from 
Alberta, Canada, attempt to identify 
whether screening of arteriovenous fi stu-
lae (AVF) represents what they describe 
as “good value for money.” Th e concept of 
‘bang for the buck’ underlies many health-
economic analyses. Typically, we consider 
this concept in the following context: ‘Th is 
new intervention will improve patient 
outcomes but will cost more as well. Is the 
extra benefi t worth at least as much as the 
extra cost?’ Th is common application of 
the ‘bang for the buck’ approach may not 
be in keeping with a more fundamental 
approach to health economics, which is to 
use a fi xed set of resources (money, staff , 
consumables, and so on) in the manner 
that produces the best patient outcomes. 
Those working in dialysis programs 
should be aware that in-center hemodi-
alysis is oft en held up as the benchmark 
maximum that society is willing to pay 
for a chronic life-saving intervention. 
With that in mind, let’s consider whether 
the work of Tonelli et al.1 produces “good 
value for money” for dialysis programs by 
both economic approaches.
An example of a traditional approach 
to determining value for money is anemia 
management. Targeting a higher than 
usual hemoglobin level may cost more 
(because of greater use of erythropoietin 
and iron) but is expected to improve qual-
ity of life. Is the incremental improvement 
in quality of life worth the extra costs of 
anemia therapy? Previous work by Tonelli 
et al. suggests that it is not.2 Th e incre-
mental cost-effectiveness ratio (ICER) 
is commonly used to answer such ques-
tions. Th e ICER is calculated by division 
of the incremental cost by the incremental 
eff ectiveness (ICER =∆C
—
  /∆E
—
  , where ∆C
—
   is 
the diff erence in mean costs and ∆E
—
   is the 
diff erence in mean eff ectiveness). Tonelli 
et al.2 suggested that raising hemoglobin 
from 9.5–10.5 g per dl to 11.0–12.0 g per 
dl cost US$55 295 per quality-adjusted 
life-year gained. Increasing hemoglobin 
further to the 12.0–12.5 g per dl range 
was associated with an ICER of $613 015 
per quality-adjusted life-year. Tonelli et 
al.2 concluded that raising hemoglobin 
to the 11.0–12.0 g per dl range was cost-
eff ective, but higher targets were not. Of 
course, before we can accept or reject a 
new intervention, we need to know the 
maximum amount that the payer would be 
willing to spend for the additional benefi t.3 
In our anemia example, what is the maxi-
mum that we are willing to pay to increase 
quality-adjusted survival? In other fi elds of 
medicine, health economists oft en point 
to the cost of dialysis as a possible maxi-
mum that we would be willing to spend 
to improve survival — a strangely circular 
argument for health economists working 
in nephrology. Other work has suggested 
that the maximum willingness-to-pay 
value for a quality-adjusted life-year is 
between $60 000 and $160 000.4,5 By these 
standards, Tonelli and colleagues’ conclu-
sions about anemia therapy seem sound. In 
their current study, Tonelli et al.1 suggest 
that it costs between $8 000 and $10 000 
to avoid one AVF failure, and they con-
clude that this “may represent good value 
for money.” Unlike in the anemia exam-
ple, where empiric work had suggested a 
possible maximum willingness to pay to 
improve quality of life, no previous work 
has suggested how much we are willing to 
spend to save a fi stula. Should we believe 
Tonelli and colleagues’ conclusions about 
AVF screening? One solution may be to 
perform additional research to quantify 
our willingness to pay in this area. Alterna-
tively, we can look to a broader economic 
view of dialysis to provide answers.
1Department of Medicine, University of Toronto, 
Toronto, Canada
Correspondence: PA McFarlane, Department of 
Medicine, University of Toronto, 61 Queen Street 
East, 9th Floor, Toronto, Ontario M5C 2T2, Canada. 
E-mail: phil.mcfarlane@utoronto.ca
